Immunosuppressive Polymeric Nanoparticles Targeting Dendritic Cells Alleviate Lupus Disease in Fcgr2b-/- Mice by Mediating Antigen-Specific Immune Tolerance
International Journal of Molecular Sciences · 2023
DOI: 10.3390/ijms24098313 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Phuriwat Khiewkamrop und 10 weiteren Autor:innen. Beteiligte Einrichtung: Research Unit in Integrative Immuno-Microbial Biochemistry and Bioresponsive Nanomaterials, Faculty of Dentistry, Chulalongkorn University, Bangkok 1…. Hauptthemen laut MEDLINE: Lupus Erythematosus, Systemic, Nanoparticles. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Thailand Science research and Innovation Fund, Chulalongkorn University, NSRF via the Program Management Unit for Human Resources & Institutional Development, Research and Innovation, and the National Research Council of Thailand.
Abstract (Originalsprache)
Dendritic cells (DCs) are the most potent antigen-presenting cells that have multifaceted functions in the control of immune activation and tolerance. Hyperresponsiveness and altered tolerogenicity of DCs contribute to the development and pathogenesis of system lupus erythematosus (SLE); therefore, DC-targeted therapies aimed at inducing specific immune tolerance have become of great importance for the treatment of SLE. This study developed a new nanoparticle (NP) containing a biodegradable PDMAEMA-PLGA copolymer for target-oriented delivery to DCs in situ. PDMAEMA-PLGA NPs provided sustained drug release and exhibited immunosuppressive activity in FLT3L and GM-CSF-derived bone marrow in conventional DCs (BM-cDCs). PDMAEMA-PLGA NPs improved dexamethasone capability to convert wild-type and Fcgr2b-/- BM-cDCs from an immunogenic to tolerogenic state, and BM-cDCs treated with dexamethasone-incorporated PDMAEMA-PLGA NPs (Dex-NPs) efficiently mediated regulatory T cell (Treg) expansion in vitro. Dex-NP therapy potentially alleviated lupus disease in Fcgr2b-/- mice by mediating Foxp3+ Treg expansion in an antigen-specific manner. Our findings substantiate the superior efficacy of DC-targeted therapy using the PDMAEMA-PLGA NP delivery system and provide further support for clinical development as a potential therapy for SLE. Furthermore, PDMAEMA-PLGA NP may be a versatile platform for DC-targeted therapy to induce antigen-specific immune tolerance to unwanted immune responses that occur in autoimmune disease, allergy, and transplant rejection.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Research Unit in Integrative Immuno-Microbial Biochemistry and Bioresponsive Nanomaterials, Faculty of Dentistry, Chulalongkorn University, Bangkok 10330, Thailand.
- Center of Excellence in Immunology and Immune-Mediated Diseases, Faculty of Medicine, Chulalongkorn University, Bangkok 10330, Thailand.
- Graduate Program in Medical Microbiology, Graduate School, Chulalongkorn University, Bangkok 10330, Thailand.
- Department of Science and Bioinnovation, Faculty of Liberal Arts and Science, Kasetsart University, Kamphaeng Saen Campus, Nakhon Pathom 73104, Thailand.
- Department of Chemistry, Faculty of Science, Chulalongkorn University, Bangkok 10330, Thailand.
- Bureau of Quality and Safety of Food, Department of Medical Sciences, Ministry of Public Health, Nonthaburi 11000, Thailand.
ORCID-Profile: Chamraj Kaewraemruaen, Patcharee Ritprajak
Förderung
- Thailand Science research and Innovation Fund, Chulalongkorn University
- NSRF via the Program Management Unit for Human Resources & Institutional Development
- Research and Innovation, and the National Research Council of Thailand
- Second Century Fund (C2F), Chulalongkorn University
- Ratchadapisek Sompoch Endowment Fund, Chulalongkorn University
- the NSRF via the Program Management Unit for Human Resources and Institutional Development
- Program Management Unit for Human Resources and Institutional Development, Research and Innovation
- Rachadapisek Sompote Matching Fund
Zitieren
APA
Khiewkamrop, P., Kaewraemruaen, C., Manipuntee, C., Saengruengrit, C., Insin, N., Leelahavanichkul, A., Kaewduangduen, W., Sonpoung, O., Ariya-Anandech, K., Hirankarn, N., & Ritprajak, P. (2023). Immunosuppressive Polymeric Nanoparticles Targeting Dendritic Cells Alleviate Lupus Disease in Fcgr2b-/- Mice by Mediating Antigen-Specific Immune Tolerance. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms24098313
Vancouver
Khiewkamrop P, Kaewraemruaen C, Manipuntee C, Saengruengrit C, Insin N, Leelahavanichkul A, et al. Immunosuppressive Polymeric Nanoparticles Targeting Dendritic Cells Alleviate Lupus Disease in Fcgr2b-/- Mice by Mediating Antigen-Specific Immune Tolerance. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms24098313
BibTeX
@article{Khiewkamrop2023,
author = {Khiewkamrop, Phuriwat and Kaewraemruaen, Chamraj and Manipuntee, Chonnavee and Saengruengrit, Chalathan and Insin, Numpon and Leelahavanichkul, Asada and Kaewduangduen, Warerat and Sonpoung, Opor and Ariya-Anandech, Kasirapat and Hirankarn, Nattiya and Ritprajak, Patcharee},
title = {Immunosuppressive Polymeric Nanoparticles Targeting Dendritic Cells Alleviate Lupus Disease in Fcgr2b-/- Mice by Mediating Antigen-Specific Immune Tolerance},
journal = {International Journal of Molecular Sciences},
year = {2023},
doi = {10.3390/ijms24098313}
}
EUVIMED